influenza vaccine

Moderna has voluntarily withdrawn its Biologics License Application (BLA) for mRNA-1083, a combination flu and COVID-19 vaccine candidate for adults 50 and older, after consultation with the FDA.

Sanofi has begun manufacturing influenza vaccines for the 2025-26 season, adopting strains recently selected by the FDA that match those already in production.

A real-world study among older US veterans showed RSV vaccines are highly effective against infection, ED/UC visits, and hospitalization.

The FDA has granted Fast Track designation to Sanofi's two combination vaccine candidates for influenza and COVID-19 in adults aged 50 and older.

Novavax has initiated a Phase 3 trial for its COVID-19-Influenza Combination (CIC) vaccine and stand-alone influenza vaccine, evaluating immunogenicity and safety.